Exelixis has a history of productive drug discovery, and we have partnered multiple compounds and programs with leading pharmaceutical and biopharmaceutical companies, including Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Genentech (a member of the Roche Group), Ipsen, Merck (known as MSD outside of the United States and Canada), Sanofi and Takeda Pharmaceutical Company Limited. These collaborations cover a variety of compounds and programs with potential for use in the treatment of cancer, inflammation, and cardiovascular and metabolic diseases.